KRAS-mutated, ER-positive low-grade serous ovarian cancer: Unraveling an exceptional response mystery.

This report demonstrates remarkable response for KRAS-mutated, ER-positive low-grade serous ovarian cancer patient treated with trametinib (MEK inhibitor) and letrozole (aromatase inhibitor), despite prior progression on similar agents including tamoxifen (estrogen modulator). In vitro investigation revealed that tamoxifen can have agonistic in addition to antagonistic effects, which could be the reason patient was not responding to combination of trametinib and tamoxifen. Our current observations suggest that drugs with different mechanisms of action targeting the same receptor may have markedly different anti-cancer activity when used in combinations. PMID: 33528846 [PubMed - as supplied by publisher]
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research